Drugs / BCG Denmark
BCG Denmark
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01906853 | Jul 2013 → Sep 2023 | allergic disease, dermatitis, respiratory tract infectious disorder | Murdoch Childrens Research Institute | Completed | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCG-Denmark | “Infants were randomly assigned to receive the BCG-Denmark vaccine or no intervention within 10 days of birth.” PMID 40464744 ↗ Jun 20251“BCG Denmark” NCT01906853 ↗ |
| Known as | Bacille Calmette-Guérin | “The beneficial off-target effects of Bacille Calmette-Guérin (BCG) vaccination potentially include protection against allergy.” PMID 39004434 ↗ Jul 2024 |
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01906853 ↗ |
| Known as | BCG vaccine - Denmark strain | “BCG vaccine - Denmark strain” NCT01906853 ↗ |
| Known as | Mycobacterium bovis BCG (Bacille Calmette Guérin), Danish Strain 1331 | “Mycobacterium bovis BCG (Bacille Calmette Guérin), Danish Strain 1331” NCT01906853 ↗ |
| Known as | Statens Serum Institute BCG vaccine | “Statens Serum Institute BCG vaccine” NCT01906853 ↗ |
| Modality | Vaccine | “BCG-Denmark vaccine” PMID 40464744 ↗ Jun 2025 |